Postradiation platinum–etoposide in adult medulloblastomas: retrospective analysis of hematological toxicity

Figures & data

Figure 1. Flow diagram: identification of patients eligible for this analysis.

EP: Platinum–etoposide; ICD: International Classification of Diseases; N: Number.

Table 1. Patient demographics.

		Total number = 13
Sex	Females	3 (23%)
	Males	10 (77%)
Race	Asian	1 (8%)
	Black	6 (46%)
	White	6 (46%)
Age at diagnosis in years	Range	22–47
	Median	33

Table 2. Clinical characteristics, treatment and outcome of patients with adult medulloblastoma treated with cisplatin and etoposide.

Patient number (study ID)	Diagnosis (histological subtype)	Molecular subgroup	Age at diagnosis (year)	Sex	Race	Risk stratification	Type of CSI	CSI total dose (Gy)	CSI fractions	Chemotherapy dose and schedule (planned)	Number of cycles/planned	Outcome	Time to last follow-up (month)^†
1	Classic MB	SHH-activated, TP53-wild-type	32	M	White	ND	Proton	54	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m2 d.1-3	4/4	Alive	50
2	Desmoplastic/nodular MB	ND	29	M	Black	ND	Photon	54	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	4/4	Alive	74
3	Classic MB	SHH-activated	36	M	Black	High	Photon	57.6	32	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	6/6	Alive	91
4	Classic MB	ND	43	M	White	High	Photon	54	30	Cis at 60 mg/m^2 d.1 Eto at 60 mg/m^2 d.1-5	4/4	Alive	148
5	Classic MB	ND	26	F	Black	ND	Photon	55.8	31	Cis at 60 mg/m^2 d.1 Eto at 60 mg/m^2 d.1-5	3/4	Deceased	16
6	Large cell/anaplastic MB	ND	33	M	White	High (+CSF)	Photon	54	30	Cis at 60 mg/m^2 d.1 Eto at 60 mg/m^2 d.1-5	2/2	Alive	171
7	Classic MB	ND	24	M	White	High (+CSF)	Photon	54	30	Cis, Eto^‡	6/6	Alive	233
8	Classic MB	SHH-activated	44	F	Black	High (LMM)	Photon	55.8	31	Cis at 60 mg/m^2 d.1 Eto at 60 mg/m^2 d.1-3	4/4	Deceased	37
9	Classic MB	Non-Wnt/non-SHH (group 4)	25	F	White	High (+CSF)	Proton	54	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	1/4	Alive	56
10	Large cell/anaplastic MB	SHH-activated, TP53-wild-type	47	M	Black	ND	Proton	49.2	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	6/6	Alive	26
11	Classic MB	SHH-activated, TP53-wild-type	46	M	Asian	ND	Photon	54	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	3/6	Alive	20
12	Large cell/anaplastic MB	SHH-activated, TP53-wild-type	22	M	Black	High	Proton	52.4	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	4/4	Alive	10
13	Desmoplastic/nodular MB	SHH-activated	33	M	White	High	Proton	54	30	Cis at 60 mg/m^2 d.1 Eto at 120 mg/m^2 d.1-3	3/4	Alive	14

† Until last contact or till date of death.

‡ Dose and schedule information not available.

+CSF: Cerebrospinal fluid positive for cancer cell; Cis: Cisplatin; CSI: Craniospinal irradiation; d.: Day; Eto: Etoposide; F: Female; LMM: Leptomeningeal metastasis: M: Male; MB: Medulloblastoma; ND: No data.

Figure 2. Illustration of hematological toxicity.

(A) Comparison of CTCAE grading of white blood cell counts, absolute neutrophil counts, and platelet counts post-craniospinal irradiation (CSI), prechemotherapy, at the count nadir and post-chemotherapy (data of photon and proton radiation therapy patients combined). (B) Blood counts during treatment over time for photon radiation therapy patients. (C) Blood counts during treatment over time for proton radiation therapy patients. Each line and color represents one individual patient.

ND: No hematological data for this time point.